三种加速诊断方案对胸痛终点指标的性能分析
这项单中心前瞻性观察研究纳入1214例急诊胸痛患者,比较mADAPT、EDACS-ADP和HEART路径对30天主要不良心脏事件(MACE)的判别性能。当MACE不含不稳定型心绞痛时,三种方案敏感性分别为mADAPT 99.1%、EDACS-ADP 99.5%、HEART路径100%;HEART路径低危分类比例最高(39.2%),其次为EDACS-ADP(31.3%)和mADAPT(29.3%)。当MACE包含不稳定型心绞痛时,敏感性降至mADAPT 96.6%、EDACS-ADP 97.3%、HEART路径97.3%,漏诊例数分别为15例、12例和12例。结论认为不含不稳定型心绞痛时三方案性能相似,HEART路径敏感性高且低危比例最高,但纳入不稳定型心绞痛后三者均未达到可接受的安全水平。
要点
- MACE不含不稳定型心绞痛时,30天MACE敏感性:mADAPT 99.1%(95%CI 96.7-99.9%)、EDACS-ADP 99.5%(95%CI 97.4-100%)、HEART路径100%(95%CI 98.3-100%)。
- 低危分类比例:HEART路径39.2%(95%CI 35.8-42.9%)最高,其次EDACS-ADP 31.3%(95%CI 28.2-34.6%)、mADAPT 29.3%(95%CI 26.4-32.5%)。
- MACE包含不稳定型心绞痛时,敏感性降至mADAPT 96.6%(95%CI 94.4-98.1%)、EDACS-ADP 97.3%(95%CI 95.3-98.6%)、HEART路径97.3%(95%CI 95.3-98.6%)。
- 漏诊例数:mADAPT 15例,EDACS-ADP 12例,HEART路径12例(MACE包含不稳定型心绞痛时)。
- 作者结论:MACE不含不稳定型心绞痛时三方案判别性能相似,HEART路径敏感性与低危比例组合最佳;纳入不稳定型心绞痛后三者均低于可接受的MACE风险。
适用人群与场景
- 急诊就诊的疑似急性冠脉综合征胸痛患者,共1214例纳入分析。
诊断标准与关键阈值
- MACE定义(不含不稳定型心绞痛):急性心肌梗死、血运重建和死亡。
- MACE定义(含不稳定型心绞痛):急性心肌梗死、血运重建、死亡和不稳定型心绞痛。
- 可接受的敏感性阈值为>99%。
研究设计与关键结果
- 单中心前瞻性观察研究,纳入1214例急诊胸痛患者,比较mADAPT、EDACS-ADP和HEART路径对30天MACE(含与不含不稳定型心绞痛)的判别性能。
- MACE不含不稳定型心绞痛时,敏感性:mADAPT 99.1%(95%CI 96.7-99.9%)、EDACS-ADP 99.5%(95%CI 97.4-100%)、HEART路径100%(95%CI 98.3-100%)。
- MACE不含不稳定型心绞痛时,低危分类比例:HEART路径39.2%(95%CI 35.8-42.9%)、EDACS-ADP 31.3%(95%CI 28.2-34.6%)、mADAPT 29.3%(95%CI 26.4-32.5%)。
- MACE包含不稳定型心绞痛时,敏感性:mADAPT 96.6%(95%CI 94.4-98.1%)、EDACS-ADP 97.3%(95%CI 95.3-98.6%)、HEART路径97.3%(95%CI 95.3-98.6%)。
- MACE包含不稳定型心绞痛时,漏诊例数:mADAPT 15例,EDACS-ADP 12例,HEART路径12例。
证据类型、等级与局限
- 证据类型:单中心前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,MACE不含不稳定型心绞痛时三种ADP判别性能相似,HEART路径敏感性与低危比例组合最佳;但将不稳定型心绞痛纳入MACE后,三种ADP均未达到可接受的安全水平,性能低于可接受的MACE风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The modified accelerated diagnostic protocol (ADP) to assess patients with chest pain symptoms using troponin as the only biomarker (mADAPT), the History, ECG, Age, Risk factors, and Troponin (HEART) pathway, and the Emergency Department Assessment of Chest Pain Rule (EDACS)-ADP, are the three most well-known ADPs for patients with chest pain. These ADPs define major adverse cardiac event (MACE) as components of acute myocardial infarction, revascularization, and death; unstable angina is not included as an endpoint.
METHODS: We performed a single-center prospective observational study comparing the performance of these 3 ADPs for patients with 30-day MACE with and without unstable angina. We hypothesized that these ADPs will have high sensitivities for MACE without unstable angina, a definition used for score derivation studies. However, when unstable angina is included in the MACE, their performances would be lower than the acceptable rate of >99% sensitivity.
RESULTS: A total of 1,214 patients were included in the analysis. When unstable angina was not included in the endpoint, sensitivities for MACE were 99.1% (95% confidence interval [CI]: 96.7-99.9%), 99.5% (95% CI: 97.4-100%), and 100% (95% CI: 98.3-100%) for mADAPT, EDACS-ADP, and HEART pathway, respectively. The HEART pathway had the highest proportion of patients classified as low risk (39.2%, 95% CI: 35.8-42.9%), followed by EDACS-ADP (31.3%, 95% CI: 28.2-34.6%) and mADAPT (29.3%, 95% CI: 26.4-32.5%). However, when unstable angina was included in the MACE, sensitivities were 96.6% (95% CI: 94.4-98.1%) for mADAPT, 97.3% (95% CI: 95.3-98.6%) for EDACS-ADP, and 97.3% (95% CI: 95.3-98.6%) for the HEART pathway, respectively. There were 15 false-negative cases with mADAPT, and 12 false-negative cases each for EDACS-ADP and HEART pathway.
CONCLUSION: All three ADPs-mADAPT, EDACS-ADP, and HEART pathway-were similarly accurate in their discriminatory performance for the risk stratification of ED patients presenting with possible ACS when unstable angina was not included in the endpoint. The HEART pathway showed the best combination of sensitivity and proportion of patients that can be classified as safe for early discharge. However, when unstable angina was added to the endpoint, all three ADPs did not show appropriate safety levels and their performances were lower than the acceptable risk of MACE.
参考来源
- Chae B, Ahn S, Ryoo SM, et al. Performance analysis considering endpoints for three accelerated diagnostic protocols for chest pain. Am J Emerg Med. 2022. PMID: 36436300. doi:10.1016/j.ajem.2022.11.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。